Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden Health Plan: Think ‘Health Security,’ Not ‘Medicare For All’

Executive Summary

The Democratic Primary focused heavily on the idea of ‘Medicare for All,’ but the emergence of former Vice President Biden as the party standard bearer – and the overwhelming impact of the COVID-19 outbreak – suggests a very different theme for the national campaign.

You may also be interested in...



Does Biden Bode Well For Pharma? Convention Sets Promising Tone For Campaign

The US pharmaceutical industry has to be pleased with the tone set by the Democratic National Convention that formally nominated Joe Biden for President. The campaign looks to be about Trump, COVID, and healing racial divisions, not drug prices.

Biden-Sanders ‘Unity Platform’: Moderate On Coverage, Extreme On Drug Pricing

The US Democratic Party will not be rallying around ‘Medicare for All’ in November. But the absence of a push for a single payer system is about the only good news for drug companies in the ‘unity platform’ released by presumptive Presidential nominee Joe Biden and his defeated rival Bernie Sanders.

US Presidential Field Narrows, But Ranking The Candidates For Pharma Is Still Complicated

It is easy to see why Sen. Bernie Sanders would be the least popular pick for biopharma executives among the contenders in the Presidential race. But for industry lobbyists, it might not be the worst outcome – at least in terms of clarifying positions.

Related Content

Topics

UsernamePublicRestriction

Register

PS142299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel